190 related articles for article (PubMed ID: 20529830)
1. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
Schmid HA; Lambertini C; van Vugt HH; Barzaghi-Rinaudo P; Schäfer J; Hillenbrand R; Sailer AW; Kaufmann M; Nuciforo P
Neuroendocrinology; 2012; 95(3):232-47. PubMed ID: 22156600
[TBL] [Abstract][Full Text] [Related]
5. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
7. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
8. Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast.
Kontogeorgos G; Thodou E; Choreftaki T
Pathol Res Pract; 2020 Sep; 216(9):153066. PubMed ID: 32825939
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
Hankus J; Tomaszewska R
Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical investigation of the expression of somatostatin receptor subtypes - should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?
Pisarek H; Pawlikowski M; Marchlewska M; Minias R; Winczyk K
Exp Clin Endocrinol Diabetes; 2015 Jun; 123(6):342-6. PubMed ID: 25962406
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
[TBL] [Abstract][Full Text] [Related]
17. Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.
Kaemmerer D; Lupp A; Peter L; Fischer E; Schulz S; Klöppel G; Hommann M
Int J Clin Exp Pathol; 2013; 6(1):49-54. PubMed ID: 23236542
[TBL] [Abstract][Full Text] [Related]
18. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
[TBL] [Abstract][Full Text] [Related]
19. Distribution and functional significance of somatostatin receptors in malignant melanoma.
Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
[TBL] [Abstract][Full Text] [Related]
20. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M
Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
